Deals Of The Week Looks At Pricing Conundrums
New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.
You may also be interested in...
An Antibiotic Anniversary Celebration: Deal-Making and Investment Are Active In Formerly Moribund Field
A year ago, the Pew Trust hosted a meeting on antibiotic development that emphasized the many barriers still discouraging investment in the field despite new legislation (the GAIN Act). Three coincidental announcements in early 2014 show that the development freeze in anti-infectives is beginning to thaw.
Armed with a $40 million Series A financing, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. With drug firms upping their interest in so-called “electroceuticals,” it could signal a shift away from certain pharmaceutical treatments.
The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.